Invention Grant
- Patent Title: Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
-
Application No.: US16081578Application Date: 2017-03-03
-
Publication No.: US10653753B2Publication Date: 2020-05-19
- Inventor: Xiaofeng Xiong
- Applicant: Eiger BioPharmaceuticals, Inc.
- Applicant Address: US CA Palo Alto
- Assignee: Eiger Biopharmaceuticals, Inc.
- Current Assignee: Eiger Biopharmaceuticals, Inc.
- Current Assignee Address: US CA Palo Alto
- Agency: Kilpatrick Townsend & Stockton LLP
- International Application: PCT/US2017/020596 WO 20170303
- International Announcement: WO2017/152014 WO 20170908
- Main IPC: A61K38/16
- IPC: A61K38/16 ; A61P11/00 ; A61P19/02 ; A61K38/26 ; A61K47/60 ; A61P3/10 ; A61K9/00
Abstract:
In one aspect, methods of treating hyperinsulinemic hypoglycemia comprising administration of an effective amount of a derivative of an exendin-4 peptide are provided. In some embodiments, the method comprises subcutaneously administering to a patient having hyperinsulinemic hypoglycemia a therapeutically effective amount of exendin(5-39).
Public/Granted literature
- US20190060413A1 Treatment Of Hyperinsulinemic Hypoglycemia With Exendin-4 Derivatives Public/Granted day:2019-02-28
Information query
IPC分类:
